Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04038489 Withdrawn - Breast Cancer Clinical Trials

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

Breast 51
Start date: October 18, 2019
Phase: Phase 2
Study type: Interventional

This study is designed to assess the safety and clinical activity of tamoxifen and the COX inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) for the treatment of high-risk estrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)- breast cancer. If successful, the study could improve long-term outcomes for a subpopulation of women with aggressive stage I-III ER+/HER2- breast cancer.

NCT ID: NCT04037852 Recruiting - Clinical trials for Breast Cancer Female

Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study

RCENSM-P
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

This study will prospectively evaluate the surgical outcomes of robotic nipple sparing mastectomy (NSM) compared with endoscopic assisted NSM or conventional NSM in the management of breast cancer. One-third patients would received R-NSM, another one-third received C-NSM while the other one-third would receive E-NSM.

NCT ID: NCT04035408 Withdrawn - Clinical trials for Breast Cancer Female

Facial Skin Health Tracking Feasibility in Breast Cancer Patients

Start date: January 24, 2020
Phase:
Study type: Observational

This feasibility study will assess if tracking objective and subjective facial skin changes over time is acceptable to pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer. There is no intervention arm and no control group. Skin health will be assessed through the instruments described below, and subjective data will be collected with self-administered questionnaires.

NCT ID: NCT04034823 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm phase II trial to evaluate the efficacy, safety and tolerability of KN035 in combination with trastuzumab and docetaxel. Eligible patient will be enrolled and receive protocol defined therapies until progressive disease, unacceptable toxicity or withdrawal of informed consent. Tumor assessment will be performed according to RECIST 1.1 criteria.

NCT ID: NCT04034589 Recruiting - Clinical trials for Metastatic Breast Cancer

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive,HR-Positive Metastatic Breast Cancer

Start date: July 17, 2019
Phase: Phase 2
Study type: Interventional

HR+/HER2+(Human epidermal growth factor receptor 2 positive and hormone receptor positive)metastatic breast cancer is a special subtype of HER2+breast cancer. Conventional guidelines recommend chemotherapy combined with trastuzumab targeted therapy for this subtype of patients. However, the choice of treatment for these patients after treatment progress is a research hotspot in this field. Pyrotinib is a new class I small molecule Tyrosine kinase inhibitors(TKI) drug with high efficacy and low toxicity after the progress of trastuzumab therapy. Fulvestrant is the most preferred single-drug therapy for HR + metastatic breast cancer recommended unanimously by the guidelines, and fulvestrant and small molecule TKI have synergistic effects. Therefore, we envisage that fulvestrant combined with Pyrotinib in the treatment of HR+/HER2+ metastatic breast cancer in clinical practice has the advantages of improving efficacy and survival. To this end, we intend to conduct a prospective, multi-center, phase II clinical trial to evaluate the efficacy and safety of erlotinib in combination with fulvestrant in patients with human epidermal growth factor receptor 2 (HER2) positive,hormone receptor-positive metastatic breast cancer.

NCT ID: NCT04033965 Completed - Breast Cancer Clinical Trials

Corellation of Mutations, TILs and Age in Breast Cancer

Start date: September 3, 1997
Phase:
Study type: Observational

Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. The investigators investigated the distribution and prognostic effect of mutations (mut) and tumor infiltrating lymphocyte (TILs) in young and elderly early breast cancer patients (pts).

NCT ID: NCT04033172 Recruiting - Breast Cancer Clinical Trials

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Pyrotinib
Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, single-center clinical study of pyrotinib plus fulvestrant as the therapy HR+/HER2+ metastatic breast cancer.

NCT ID: NCT04032080 Completed - Clinical trials for Triple Negative Breast Cancer

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Start date: September 5, 2019
Phase: Phase 2
Study type: Interventional

This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.

NCT ID: NCT04031885 Terminated - Clinical trials for Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Start date: August 14, 2019
Phase: Phase 4
Study type: Interventional

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.

NCT ID: NCT04031703 Completed - Breast Cancer Clinical Trials

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Start date: January 1, 2011
Phase: Phase 3
Study type: Interventional

This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer